Category

AstraZeneca

page 1

Imperial Chemical Industries

former British chemicals, paints and pharmaceuticals company

Alexion Pharmaceuticals

American company

Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections (one injection per monoclonal antibody, given in immediate succession).

embolic and thrombotic events after COVID-19 vaccination

post vaccination adverse effects

AstraZeneca (United States)

MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.

former Swedish pharmaceutical company; merged 1999 with Zeneca Group into Astra Zeneca

Amylin Pharmaceuticals